Lonza Aligns Business Structure, Adds Executive Position
26th February 2019
Swiss fine chemicals producer and pharmaceutical industry supplier Lonza announced on Feb. 25, that it will realign its structure and create an additional executive position.
The former Pharma & Biotech and Consumer Health & Nutrition business units will be combined in the new Pharma Biotech & Nutrition (LPBN) segment.
Stefan Stoffel, who joined Lonza in 1991, will be responsible for the operating business of the LPBN segment in a newly created position as chief operating officer (COO), effective Mar. 1.
In addition to Stoffel, the company's future management will therefore consist of Marc Funk, Sven Abend (COO of the LSI segment) and Rodolfo Savitzky (chief financial officer, CFO).
As already announced by Lonza in January, Funk will take over as CEO from Richard Ridinger on Mar. 1, 2019.
The business units Consumer Product Ingredients and Consumer & Resources Protection will remain in Lonza’s Specialty Ingredients (LSI) segment.
Funk commented: “Our new structure will nurture synergies and increase operational efficiency, which will create customer benefits. More importantly, it will enable Lonza to develop a more compelling offer across pharma, biotech and nutrition and to extend our competitive advantage in the market. Stefan is a well-regarded, long-established and strong leader in the Lonza business. His oversight of LPBN segment operations will help us to galvanize our offering and capitalize on future opportunities.”
For more information visit www.chemanager-online.com/en/